期刊
ARCHIVES OF NEUROLOGY
卷 69, 期 10, 页码 1255-1258出版社
AMER MEDICAL ASSOC
DOI: 10.1001/archneurol.2012.540
关键词
-
资金
- NIA NIH HHS [R21 AG047484] Funding Source: Medline
- NINDS NIH HHS [U01 NS074501] Funding Source: Medline
Although significant progress has occurred in the past 20 years regarding our understanding of Alzheimer disease pathogenesis, we have yet to identify disease-modifying therapeutics capable of substantially altering the clinical course of this prevalent neurodegenerative disease. In this short review, we discuss 2 approaches that are currently being tested clinically (gamma-secretase inhibition and gamma-secretase modulation) and emphasize the significant differences between these 2 therapeutic approaches. We also discuss certain genetic- and biomarker-based translational and clinical trial paradigms that may assist in developing a useful therapeutic agent. Arch Neurol. 2012;69(10):1255-1258. Published online July 16, 2012. doi:10.1001/archneurol.2012.540
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据